GENELUX CORPORATION Basic Shares Outstanding (Weighted Average)
GENELUX CORPORATION (GNLX) reported Basic Shares Outstanding (Weighted Average) of 44.96 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-13
- GENELUX CORPORATION weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 44.96M shares, a 18.48% increase year-over-year.
- GENELUX CORPORATION weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 44.15M shares, a 26.41% increase year-over-year.
- GENELUX CORPORATION weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 38.10M shares, a 10.17% increase year-over-year.
- GENELUX CORPORATION weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 37.89M shares, a 9.73% increase year-over-year.
- GENELUX CORPORATION weighted average number of shares outstanding, basic for fiscal 2025 was 37.18M shares, a 18.21% increase from fiscal 2024.
- GENELUX CORPORATION weighted average number of shares outstanding, basic for fiscal 2024 was 31.45M shares, a 0.00% change from fiscal 2023.
- GENELUX CORPORATION weighted average number of shares outstanding, basic for fiscal 2023 was 31.45M shares, a 244.99% increase from fiscal 2022.
- GENELUX CORPORATION weighted average number of shares outstanding, basic for fiscal 2022 was 9.12M shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month | Weighted Average Number of Shares Outstanding, Basic 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | 44.96M shares 10-Q · filed 2026-08-13 | 44.56M shares 10-Q · filed 2026-08-13 | 42.40M shares derived: average of 3 quarters · filed 2026-08-13 | 41.28M shares derived: average of 4 quarters · filed 2026-08-13 | |
| 2026-03-31 | 44.15M shares 10-Q · filed 2026-05-07 | 41.13M shares derived: average of 2 quarters · filed 2026-05-07 | 40.05M shares derived: average of 3 quarters · filed 2026-05-07 | 39.52M shares derived: average of 4 quarters · filed 2026-08-13 | |
| 2025-12-31 | 38.10M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | 38.00M shares derived: average of 2 quarters · filed 2026-03-19 | 37.98M shares derived: average of 3 quarters · filed 2026-08-13 | 37.18M shares 10-K · filed 2026-03-19 | |
| 2025-09-30 | 37.89M shares 10-Q · filed 2025-11-05 | 37.92M shares derived: average of 2 quarters · filed 2026-08-13 | 36.87M shares 10-Q · filed 2025-11-05 | 36.34M shares derived: average of 4 quarters · filed 2026-08-13 | |
| 2025-06-30 | 37.95M shares 10-Q · filed 2026-08-13 | 36.35M shares 10-Q · filed 2026-08-13 | 35.82M shares derived: average of 3 quarters · filed 2026-08-13 | 35.50M shares derived: average of 4 quarters · filed 2026-08-13 | |
| 2025-03-31 | 34.93M shares 10-Q · filed 2026-05-07 | 34.76M shares derived: average of 2 quarters · filed 2026-05-07 | 34.68M shares derived: average of 3 quarters · filed 2026-05-07 | 33.43M shares derived: average of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | 34.59M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | 34.56M shares derived: average of 2 quarters · filed 2026-03-19 | 32.94M shares derived: average of 3 quarters · filed 2026-03-19 | 31.45M shares 10-K · filed 2026-03-19 | |
| 2024-09-30 | 34.53M shares 10-Q · filed 2025-11-05 | 32.11M shares derived: average of 2 quarters · filed 2025-11-05 | 30.41M shares 10-Q · filed 2025-11-05 | 36.49M shares derived: average of 4 quarters · filed 2026-03-19 | |
| 2024-06-30 | 29.69M shares 10-Q · filed 2025-08-07 | 28.31M shares 10-Q · filed 2025-08-07 | 37.14M shares derived: average of 3 quarters · filed 2026-03-19 | 34.41M shares derived: average of 4 quarters · filed 2026-03-19 | |
| 2024-03-31 | 26.85M shares 10-Q · filed 2025-05-06 | 40.86M shares derived: average of 2 quarters · filed 2026-03-19 | 35.98M shares derived: average of 3 quarters · filed 2026-03-19 | 33.25M shares derived: average of 4 quarters · filed 2026-03-19 | |
| 2023-12-31 | 54.88M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | 40.54M shares derived: average of 2 quarters · filed 2026-03-19 | 35.39M shares derived: average of 3 quarters · filed 2026-03-19 | 31.45M shares 10-K · filed 2026-03-19 | 24.43M shares 10-K · filed 2024-03-29 |
| 2023-09-30 | 26.21M shares 10-Q · filed 2024-11-14 | 25.64M shares derived: average of 2 quarters · filed 2024-11-14 | 23.64M shares 10-Q · filed 2024-11-14 | 20.00M shares derived: average of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | 25.07M shares 10-Q · filed 2024-08-14 | 22.33M shares 10-Q · filed 2024-08-14 | 17.92M shares derived: average of 3 quarters · filed 2024-08-14 | 15.72M shares derived: average of 4 quarters · filed 2024-08-14 | |
| 2023-03-31 | 19.58M shares 10-Q · filed 2024-05-09 | 14.35M shares derived: average of 2 quarters · filed 2024-05-09 | 12.61M shares derived: average of 3 quarters · filed 2024-05-09 | 11.73M shares derived: average of 4 quarters · filed 2024-05-09 | |
| 2022-12-31 | 9.13M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | 9.12M shares derived: average of 2 quarters · filed 2024-03-29 | 9.12M shares derived: average of 3 quarters · filed 2024-03-29 | 9.12M shares 10-K · filed 2024-03-29 | |
| 2022-09-30 | 9.12M shares 10-Q · filed 2023-11-14 | 9.11M shares derived: average of 2 quarters · filed 2023-11-14 | 9.11M shares 10-Q · filed 2023-11-14 | ||
| 2022-06-30 | 9.11M shares 10-Q · filed 2023-08-14 | 9.11M shares 10-Q · filed 2023-08-14 | |||
| 2022-03-31 | 9.11M shares 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |